Uniunea Europeană - lituaniană - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Uniunea Europeană - lituaniană - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus eritema, sisteminis - imunosupresantai - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Uniunea Europeană - lituaniană - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - imunosupresantai - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.